Joanne E Sordillo1, Christina V Scirica1, Sheryl L Rifas-Shiman2, Matthew W Gillman2, Supinda Bunyavanich3, Carlos A Camargo1, Scott T Weiss1, Diane R Gold1, Augusto A Litonjua4. 1. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass. 2. Obesity Prevention Program, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Mass. 3. Child Health and Development Institute, Mount Sinai Hospital, New York, NY. 4. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass. Electronic address: augusto.litonjua@channing.harvard.edu.
Abstract
BACKGROUND: Several studies have reported an association between use of over-the-counter antipyretics during pregnancy or infancy and increased asthma risk. An important potential limitation of these observational studies is confounding by indication. OBJECTIVES: We investigated the association of antipyretic intake during pregnancy and during the first year of life (infancy) with asthma-related outcomes before and after controlling for early-life respiratory tract infections. METHODS: We included 1490 mother-child pairs in Project Viva, a longitudinal prebirth cohort study. We categorized prenatal acetaminophen exposure as the maximum intake (never, 1-9 times, or ≥10 times) in early pregnancy or midpregnancy and ibuprofen intake as presence or absence in early pregnancy. We expressed intake of antipyretics in infancy as never, 1 to 5 times, 6 to 10 times, or more than 10 times. We examined the associations of acetaminophen and ibuprofen (per unit increase in exposure category) during pregnancy and infancy with wheeze, asthma, and allergen sensitization in early childhood (3-5 years of age, n = 1419) and midchildhood (7-10 years of age, n = 1220). RESULTS: Unadjusted models showed an increased asthma risk in early childhood for higher infant acetaminophen (odds ratio [OR], 1.21; 95% CI 1.04-1.41) and ibuprofen (OR, 1.35; 95% CI, 1.19-1.52) intake. Controlling for respiratory tract infections attenuated estimates for acetaminophen (OR, 1.03; 95% CI, 0.88-1.22) and ibuprofen (OR, 1.19; 95% CI, 1.05-1.36). Prenatal acetaminophen was associated with increased asthma (OR, 1.26; 95% CI, 1.02-1.58) in early childhood but not midchildhood. CONCLUSIONS: Adjustment for respiratory tract infections in early life substantially diminished associations between infant antipyretic use and early childhood asthma. Respiratory tract infections should be accounted for in studies of antipyretics and asthma to mitigate bias caused by confounding by indication.
BACKGROUND: Several studies have reported an association between use of over-the-counter antipyretics during pregnancy or infancy and increased asthma risk. An important potential limitation of these observational studies is confounding by indication. OBJECTIVES: We investigated the association of antipyretic intake during pregnancy and during the first year of life (infancy) with asthma-related outcomes before and after controlling for early-life respiratory tract infections. METHODS: We included 1490 mother-child pairs in Project Viva, a longitudinal prebirth cohort study. We categorized prenatal acetaminophen exposure as the maximum intake (never, 1-9 times, or ≥10 times) in early pregnancy or midpregnancy and ibuprofen intake as presence or absence in early pregnancy. We expressed intake of antipyretics in infancy as never, 1 to 5 times, 6 to 10 times, or more than 10 times. We examined the associations of acetaminophen and ibuprofen (per unit increase in exposure category) during pregnancy and infancy with wheeze, asthma, and allergen sensitization in early childhood (3-5 years of age, n = 1419) and midchildhood (7-10 years of age, n = 1220). RESULTS: Unadjusted models showed an increased asthma risk in early childhood for higher infantacetaminophen (odds ratio [OR], 1.21; 95% CI 1.04-1.41) and ibuprofen (OR, 1.35; 95% CI, 1.19-1.52) intake. Controlling for respiratory tract infections attenuated estimates for acetaminophen (OR, 1.03; 95% CI, 0.88-1.22) and ibuprofen (OR, 1.19; 95% CI, 1.05-1.36). Prenatal acetaminophen was associated with increased asthma (OR, 1.26; 95% CI, 1.02-1.58) in early childhood but not midchildhood. CONCLUSIONS: Adjustment for respiratory tract infections in early life substantially diminished associations between infant antipyretic use and early childhood asthma. Respiratory tract infections should be accounted for in studies of antipyretics and asthma to mitigate bias caused by confounding by indication.
Authors: Lisa B Signorello; Joseph K McLaughlin; Loren Lipworth; Søren Friis; Henrik Toft Sørensen; William J Blot Journal: Am J Ther Date: 2002 May-Jun Impact factor: 2.688
Authors: Matthew W Gillman; Janet W Rich-Edwards; Sheryl L Rifas-Shiman; Ellice S Lieberman; Ken P Kleinman; Steven E Lipshultz Journal: J Pediatr Date: 2004-02 Impact factor: 4.406
Authors: R Graham Barr; Catherine C Wentowski; Gary C Curhan; Samuel C Somers; Meir J Stampfer; Joel Schwartz; Frank E Speizer; Carlos A Camargo Journal: Am J Respir Crit Care Med Date: 2004-01-07 Impact factor: 21.405
Authors: William J Sheehan; David T Mauger; Ian M Paul; James N Moy; Susan J Boehmer; Stanley J Szefler; Anne M Fitzpatrick; Daniel J Jackson; Leonard B Bacharier; Michael D Cabana; Ronina Covar; Fernando Holguin; Robert F Lemanske; Fernando D Martinez; Jacqueline A Pongracic; Avraham Beigelman; Sachin N Baxi; Mindy Benson; Kathryn Blake; James F Chmiel; Cori L Daines; Michael O Daines; Jonathan M Gaffin; Deborah A Gentile; W Adam Gower; Elliot Israel; Harsha V Kumar; Jason E Lang; Stephen C Lazarus; John J Lima; Ngoc Ly; Jyothi Marbin; Wayne J Morgan; Ross E Myers; J Tod Olin; Stephen P Peters; Hengameh H Raissy; Rachel G Robison; Kristie Ross; Christine A Sorkness; Shannon M Thyne; Michael E Wechsler; Wanda Phipatanakul Journal: N Engl J Med Date: 2016-08-18 Impact factor: 91.245
Authors: Joshua L Kennedy; Richard C Kurten; Sandra McCullough; Reynold A Panettieri; Cynthia Koziol-White; Stacie M Jones; Katherine Caid; Pritmohinder S Gill; Dean Roberts; Hartmut Jaeschke; Mitchell R McGill; Laura James Journal: Xenobiotica Date: 2019-01-30 Impact factor: 1.908
Authors: Joanne E Sordillo; Sheryl L Rifas-Shiman; Karen Switkowski; Brent Coull; Heike Gibson; Mary Rice; Thomas A E Platts-Mills; Itai Kloog; Augusto A Litonjua; Diane R Gold; Emily Oken Journal: J Allergy Clin Immunol Date: 2019-08-19 Impact factor: 10.793
Authors: Alies Sjoukes; Roderick P Venekamp; Alma C van de Pol; Alastair D Hay; Paul Little; Anne Gm Schilder; Roger Amj Damoiseaux Journal: Cochrane Database Syst Rev Date: 2016-12-15